FORM 4
--------

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person +	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer					
1. Name and Address of Reporting Person –	2. Issuel Funde and Treker of Frading Symbol	(Check all applicable)					
Liawatidewi Yakob	Amphastar Pharmaceuticals, Inc. [						
	AMPH ]	Director 10% Owner					
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	_X_ Officer (give title below) Other (specify below)					
		EVP Corp Admin Center					
C/O AMPHASTAR	6/14/2022						
PHARMACEUTICALS, INC., 11570							
6TH STREET							
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)					
RANCHO CUCAMONGA, CA 91730 (City) (State) (Zip)		X _ Form filed by One Reporting Person Form filed by More than One Reporting Person					

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

			- <b>1</b>	·, ·]		-,			
1. Title of Security (Instr. 3)	2. Trans. Date			4. Securities Acquired (A or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Direct (D)	7. Nature of Indirect Beneficial Ownership
		Code	v	Amount	(A) or (D)	Price		or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock	6/14/2022	F		128 ( <u>1</u> )	D	\$31.02	61607	D	
Common Stock							2459	1	See footnote <sup>(2)</sup>

## Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	4. Trans. (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		and Expiration Date		Securities Underlying Derivative Security		Derivative Security (Instr. 5)	Securities Beneficially Owned Following	Ownership o Form of E Derivative C	Beneficial Ownership (Instr. 4)
			Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	or Indirect (I) (Instr. 4)	

## **Explanation of Responses:**

(1) The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs.

(2) The reported shares are held of record by the Yakob and Sunmoon Trust dated July 25, 2013 for which the reporting person serves as a trustee.

#### **Reporting Owners**

Reporting Owner Name / Address		Relationships							
		10% Owner	Officer	Other					
Liawatidewi Yakob C/O AMPHASTAR PHARMACEUTICALS, INC 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	2		EVP Corp Admin Center						

### Signatures

/s/ Eva Wen, by power of attorney \*\*Signature of Reporting Person

6/15/2022 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

number.